Kura Oncology (NASDAQ:KURA) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $32.00 price target on the stock.

Other research analysts have also issued research reports about the company. Wedbush restated an outperform rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Wednesday, February 28th. JMP Securities boosted their price objective on Kura Oncology from $22.00 to $32.00 and gave the company a market outperform rating in a research report on Wednesday, January 31st. Finally, StockNews.com lowered Kura Oncology from a hold rating to a sell rating in a research report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus target price of $28.28.

Kura Oncology Price Performance

Shares of KURA opened at $18.19 on Monday. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -8.75 and a beta of 0.85. The stock has a 50 day moving average of $20.73 and a 200-day moving average of $15.35. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52 week low of $7.41 and a 52 week high of $24.17.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01. During the same period last year, the business posted ($0.49) EPS. As a group, analysts forecast that Kura Oncology will post -2.35 EPS for the current year.

Insiders Place Their Bets

In other Kura Oncology news, CEO Troy Edward Wilson sold 91,052 shares of the business’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $20.23, for a total transaction of $1,841,981.96. Following the completion of the transaction, the chief executive officer now owns 559 shares in the company, valued at approximately $11,308.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Troy Edward Wilson sold 91,052 shares of the business’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $20.23, for a total value of $1,841,981.96. Following the sale, the chief executive officer now owns 559 shares of the company’s stock, valued at approximately $11,308.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Teresa Brophy Bair sold 2,053 shares of the business’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $36,543.40. Following the completion of the sale, the insider now directly owns 68,979 shares in the company, valued at approximately $1,227,826.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 96,919 shares of company stock worth $1,946,415. 5.50% of the stock is owned by company insiders.

Institutional Trading of Kura Oncology

Hedge funds and other institutional investors have recently modified their holdings of the company. Signaturefd LLC raised its stake in shares of Kura Oncology by 40.4% in the 4th quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after buying an additional 1,449 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Kura Oncology by 352.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock worth $124,000 after purchasing an additional 6,692 shares during the period. Saxon Interests Inc. acquired a new stake in shares of Kura Oncology during the first quarter worth $201,000. Pale Fire Capital SE acquired a new stake in shares of Kura Oncology during the third quarter worth $92,000. Finally, E Fund Management Co. Ltd. raised its position in shares of Kura Oncology by 12.2% during the third quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock worth $109,000 after purchasing an additional 1,301 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.